Tedizolid may be effective in MRSA-associated skin infections
The novel oxazolidinone tedizolid appears to be clinically superior to vancomycin and comparable with other monotherapy drugs in treating serious skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA), according to a systematic review and network meta-analysis.
Tedizolid has been shown in phase III noninferiority trials to have a favourable tolerability profile and is as effective as linezolid against a wide range of Gram-positive pathogens in the treatment of acute bacterial skin and skin structure infections (ABSSSI). [Antimicrob Agents Chemother 2015;59:864-71]
A total of 10 databases were searched for eligible studies consisting of randomized clinical trials (RCTs) published in English that investigated the efficacy of tedizolid or other established antimicrobials (namely, vancomycin, linezolid, daptomycin, teicoplanin, tigecycline, ceftaroline or telavancin) as monotherapy in adults with suspected or documented MRSA-ABSSSI, or complicated skin and skin structure infections (cSSSI).
Outcome measures included clinical response rate at end of therapy (EOT), post-therapy evaluation (PTE) or test-of-cure (TOC) assessment as well as serious adverse events (AEs) leading to discontinuation of treatment.
Of the 3,618 identified records, 15 RCTs were included for analysis. Tedizolid was shown to be superior in terms of clinical response at EOT (odds ratio [OR], 1.7) and had higher odds of clinical response at PTE or TOC (OR, 1.6) compared with vancomycin, but not with other comparators. No difference was observed among all treatments for discontinuation due to AEs.“These findings suggest that tedizolid provides an alternative option for the management of serious skin infections caused by suspected or documented MRSA,” said researchers, adding that caution must be observed in interpreting the study results.